EFFECT OF SYSTEMIC IMMUNE-INFLAMMATION INDEX ON MORTALITY IN PATIENTS WITH PERIPHERAL ARTERY DISEASE

Year 2025, Volume: 26 Issue: 1, 28 - 32, 27.01.2025

İbrahim Etem Dural , Zafer Yalım , Uğur Aksu , Mehmet Özgeyik , Serkan Gökaslan , Ömer Faruk Yılmaz

https://doi.org/10.18229/kocatepetip.1442806

Abstract

OBJECTIVE: Peripheral artery disease ranks as the third leading
cause of death and illness following coronary artery disease
and cerebrovascular disease among atherosclerotic conditions,
representing a significant health concern worldwide. Our study
aims to explore the association between the systemic immune-
inflammation index a combined marker of inflammation
and aggregation and survival in patients with peripheral artery
disease.
MATERIAL AND METHODS: In this retrospective cohort study,
we examined the medical records of 432 individuals diagnosed
with peripheral artery disease between the years 2010 and
2020. The systemic immune-inflammation index was calculated
based on platelet to lymphocyte ratios from the patients’
complete blood count tests, and the relationship between this
index and mortality was assessed using the Kaplan-Meier survival
analysis.
RESULTS: Our findings demonstrate that the systemic immune-
inflammation index is an independent predictor of mortality
in peripheral artery disease. Statistical analyses have shown
that higher values of the systemic immune-inflammation index
(> 854), correlate with increased mortality in individuals with
peripheral artery disease and type two diabetes mellitus (OR:
1.02, %95 GA: 0.98-1.04, p<0.001).
CONCLUSIONS: In conclusion, the systemic immune-inflammation
index is a significant determinant of survival in patients
with peripheral artery disease. These results can enhance
our understanding of the role of inflammation and immune
response in the management of peripheral artery disease and
may contribute to developing potential therapeutic strategies.

Keywords

Peripheral Artery Disease, Systemic immune-inflammation index, Mortality, Type 2 diabetes mellitus, Epidemiology.

PERİFERİK ARTER HASTALIĞI OLAN HASTALARDA SİSTEMİK İMMÜN-ENFLAMASYON İNDEKSİNİN MORTALİTE ÜZERİNE ETKİSİ

Abstract

AMAÇ: Aterosklerotik hastalıklar arasında koroner arter hastalığı
ve serebrovasküler hastalıktan sonra üçüncü sıradaki mortalite
ve morbidite nedeni olan periferik arter hastalığı, dünya genelinde
önemli bir sağlık sorunudur. Çalışmamız, inflamasyon
ve agregasyonun birleşik bir belirteci olan sistemik immün-inflamasyon
indeksi ile periferik arter hastalığı olan hastalarda
sağkalım arasındaki ilişkiyi araştırmayı amaçlamaktadır.
GEREÇ VE YÖNTEM: Bu retrospektif kohort çalışmasında, 2010-
2020 yılları arasında periferik arter hastalığı tanısı konmuş 432
bireyin hasta kayıtları incelenmiştir. Hastaların hemogram testlerindeki
trombosit-lenfosit oranlarından yola çıkarak sistemik
immün-inflamasyon indeksi hesaplanmış ve bu indeks ile mortalite
arasındaki ilişki Kaplan Meier analizi ile değerlendirilmiştir.
BULGULAR: Çalışma bulgularımız, sistemik immün-inflamasyon
indeksinin periferik arter hastalığında mortalitenin bağımsız
bir belirleyicisi olduğunu ortaya koymuştur. İstatistiksel analizler,
yüksek sistemik immün-inflamasyon indeksi değerlerinin
(> 854), periferik arter hastalığı ve tip 2 diyabet mellituslu bireylerde
artmış mortalite ile ilişkili olduğunu göstermiştir (OR: 1.02,
%95 GA: 0.98-1.04, p<0.001).
SONUÇ: Sonuç olarak, sistemik immün-inflamasyon indeksi,
periferik arter hastalığı olan hastalarda sağkalımı öngördüren
önemli bir faktördür. Bu bulgular, periferik arter hastalığı yönetiminde
inflamasyon ve immün yanıtın rolünü daha iyi anlamamıza
yardımcı olabilir ve potansiyel tedavi stratejilerinin geliştirilmesine
katkı sağlayabilir.

Keywords

Periferik arter hastalığı, Sistemik immün- inflamasyon indeks, Ölüm oranı, Tip 2 diabetes mellitus, Epidemiyoloji.

References

• 1. Criqui MH, Aboyans V. Epidemiology of Peripheral Artery Disease. Circ Res. 2015;116(9):1509–26.
• 2. Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet. 2013;382(9901):1329– 40.
• 3. Klein AJ, Ross CB. Endovascular treatment of lower extremity peripheral arterial disease. Trends Cardiovasc Med. 2016;26(6):495–512.
• 4. Rymer JA, Swaminathan RV, Aday AW, et al. The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target? Curr Cardiol Rep. 2021;23(3):13.
• 5. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis. 2016;109(12):708–15.
• 6. Zhang Z, Chen Z. Higher Systemic Immune-Inflammation Index is Associated With Higher Likelihood of Peripheral Arterial Disease. Ann Vasc Surg. 2022;84:322–6.
• 7. Onofrei V, Crișan A, Adam CA, et al. The Role Played by Novel Inflammatory Markers in Assessment of Peripheral Artery Disease. Medicina (B Aires). 2023;59(9):1557.
• 8. Rahman MS, Woollard K. Atherosclerosis. In 2017. 2017:1003:121-144.
• 9. Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis. 2020;293:94–100.
• 10. Vrsalovic M, Vucur K, Vrsalovic Presecki A, et al. Impact of diabetes on mortality in peripheral artery disease: a meta‐analysis. Clin Cardiol. 2017;40(5):287–91.
• 11. Özgür Y. Relationship between Vitamin D Deficiency, Albuminuria, Peripheral Artery Disease and 5-year Mortality in Chronic Kidney Disease. J Coll Physicians Surg Pak. 2021;31(6):644-650.
• 12. Kou M, Ding N, Ballew SH, Salameh MJ, Martin SS, et al. Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2021;41(3):1229–38.
• 13. Yalım Z, Aldemir M, Emren SV. Association of Inflammatory Markers with Multisite Artery Disease in Patients with Peripheral Arterial Disease. Clínica e Investigación en Arteriosclerosis. 2021;33(2):55–61.
• 14. Emir S, Aydin M, Can G, et al. Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR. 2015;19(19):3613-8.
• 15. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratislava Medical Journal. 2021;122(07):474–88.
• 16. Kelesoglu S, Yilmaz Y, Elcık D, Kalay N. Systemic immune inflammation index: a novel predictor for coronary collateral circulation. Perfusion. 2022;37(6):605–12.
• 17. Wang Y, Zhuang Y, Lin C, et al. The neutrophil-to-lymphocyte ratio is associated with coronary heart disease risk in adults: A population-based study. PLoS One. 2024;19(2):e0296838.
• 18. Yang Y, Wu C, Hsu P, et al. Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5): e13230.
• 19. Aydin C, Alpsoy Ş, Akyüz A, et al. Could the systemic immune-inflammation index be a predictor to estimate cerebrovascular events in hypertensive patients? Blood Press Monit. 2022;27(1):33–8.
• 20. Ketenciler S, Ada S. Systemic immune inflammation index: is it a new marker for contrast-induced nephropathy? Anatolian Current Medical Journal. 2022;4(3):311–6.
• 21. Ozturk S, Erdoğan M, Turan Y. Systemic immune-inflammation index and high-sensitivity cardiac troponin T in acute coronary syndromes. Acta Medica Alanya. 2021;5(3):218–25.
• 22. Chen W, Chen K, Xu Z, et al. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predict Mortality in Patients with Diabetic Foot Ulcers Undergoing Amputations. Diabetes Metab Syndr Obes. 2021;14:821-829